Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.

In contrast, the improvement in the PD-L1 negative subgroup did not reach statistical significance (11.8% vs. 6.7%; RD = 0.05, 95% CI = −0.01 to 0.11, P = .10).

also in 111,027 other papers

However, the conclusions of these 2 trials differed: MATTERHORN met its primary EFS endpoint and demonstrated a statistically significant benefit with durvalumab-based chemoimmunotherapy, whereas KEYNOTE-585 did not achieve a statistically significant improvement (HR = 0.81, 95% CI = 0.67 to 0.98), showing only a numerical trend favoring pembrolizumab-based therapy.

also in 1,012 other papers

The safety analysis showed a trend toward increased grade ≥3 TRAEs and a significantly higher rate of treatment-related discontinuation in the chemoimmunotherapy group compared with chemotherapy alone.

also in 53,322 other papers